Cargando…

Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

BACKGROUND: Patients with atrial fibrillation who undergo intracoronary stenting traditionally are treated with a vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT), yet this treatment leads to high risks of bleeding. We hypothesized that a regimen of rivaroxaban plus a P2Y(12) inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gibson, C. Michael, Pinto, Duane S., Chi, Gerald, Arbetter, Douglas, Yee, Megan, Mehran, Roxana, Bode, Christoph, Halperin, Jonathan, Verheugt, Freek W.A., Wildgoose, Peter, Burton, Paul, van Eickels, Martin, Korjian, Serge, Daaboul, Yazan, Jain, Purva, Lip, Gregory Y.H., Cohen, Marc, Peterson, Eric D., Fox, Keith A.A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266420/ https://www.ncbi.nlm.nih.gov/pubmed/27881555 http://dx.doi.org/10.1161/CIRCULATIONAHA.116.025783

Ejemplares similares

Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy
por: Gibson, C. Michael, et al.
Publicado: (2017)

Pheochromocytoma Presenting as Partial HELLP Syndrome
por: Daaboul, Yazan, et al.
Publicado: (2015)

Dual antiplatelet agents and Rivaroxaban for massive intracoronary thrombus in STEMI
por: Jamal, Nasiruddin, et al.
Publicado: (2015)

Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Post‐Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACS‐TIMI 46 and ATLAS ACS 2‐TIMI 51
por: Gibson, William J., et al.
Publicado: (2019)

Anticoagulation in patients with mechanical heart valves: follow the guidelines!
por: Verheugt, Freek W.A.
Publicado: (2015)

Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden
por: Begum, Najida, et al.
Publicado: (2015)

The role of aspirin in women’s health
por: Verheugt, Freek WA, et al.
Publicado: (2011)

Medical education in a foreign language and history-taking in the native language in Lebanon – a nationwide survey
por: Abi Raad, Vanda, et al.
Publicado: (2016)

Intracoronary Imaging, Cholesterol Efflux, and Transcriptomics after Intensive Statin Treatment in Diabetes
por: Chamaria, Surbhi, et al.
Publicado: (2017)

Anticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decade
por: Atar, Dan, et al.
Publicado: (2014)

A Novel Biological Strategy for Myocardial Protection by Intracoronary Delivery of Mitochondria: Safety and Efficacy
por: Shin, Borami, et al.
Publicado: (2019)

Effectiveness of two intensive treatment methods for smoking cessation and relapse prevention in patients with coronary heart disease: study protocol and baseline description
por: Berndt, Nadine, et al.
Publicado: (2012)

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation
por: Camm, A John, et al.
Publicado: (2014)

Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis
por: Cano, Stefan, et al.
Publicado: (2018)

Rivaroxaban for the Treatment of Pulmonary Embolism
por: Vanassche, Thomas, et al.
Publicado: (2013)

Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)
por: Michael Gibson, C., et al.
Publicado: (2016)

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
por: Kirchhof, Paulus, et al.
Publicado: (2020)

Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
por: ten Berg, Jurriën M, et al.
Publicado: (2001)

Rivaroxaban Precision Dosing Strategy for Real‐World Atrial Fibrillation Patients
por: Konicki, Robyn, et al.
Publicado: (2020)

Complete revascularization in elderly patients with myocardial infarction—a safe, effective, and necessary strategy?
por: Gue, Ying X., et al.
Publicado: (2023)

Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry
por: Kakkar, Ajay K., et al.
Publicado: (2013)

Repeated intracoronary lithotripsy as a treatment for rebel stent underexpansion
por: Valencia, José, et al.
Publicado: (2021)

Intracoronary Lithoplasty in Percutaneous Treatment of Challenging Calcified Coronary Lesions
por: Marchese, Alfredo, et al.
Publicado: (2020)

Cerebral blood flow changes during tilt table testing in healthy volunteers, as assessed by Doppler imaging of the carotid and vertebral arteries
por: van Campen, C. (Linda).M.C., et al.
Publicado: (2018)

Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial
por: Hohnloser, Stefan H., et al.
Publicado: (2016)

Successful treatment of livedoid vasculopathy with rivaroxaban
por: Evans, John M., et al.
Publicado: (2015)

Rivaroxaban for the treatment of cerebral venous thrombosis
por: Esmaeili, Sara, et al.
Publicado: (2021)

Stroke‐prevention strategies in North American patients with atrial fibrillation: The GLORIA‐AF registry program
por: McIntyre, William F., et al.
Publicado: (2018)

XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
por: Camm, A. John, et al.
Publicado: (2016)

Omega-3 polyunsaturated fatty acids: a necessity for a comprehensive secondary prevention strategy
por: Patel, Jeetesh V, et al.
Publicado: (2009)

Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
por: Bauersachs, Rupert, et al.
Publicado: (2020)

The stability of flow velocity and intracoronary resistance in the intracoronary electrocardiogram-triggered pressure ratio
por: Nakayama, Masafumi, et al.
Publicado: (2021)

Intracoronary Lithotripsy in Percutaneous Treatment of Calcific Left Main Coronary Stenoses
por: Salazar, Carlos H., et al.
Publicado: (2019)

Shockwave intracoronary lithotripsy for the treatment of calcium-mediated undilatable in-stent restenosis
por: Kuzemczak, Michał, et al.
Publicado: (2022)

Stroke prevention with rivaroxaban in higher‐risk populations with atrial fibrillation
por: Diener, H.‐C., et al.
Publicado: (2015)

Caprini Scores, Risk Stratification, and Rivaroxaban in Plastic Surgery: Time to Reconsider Our Strategy
por: Swanson, Eric
Publicado: (2016)

Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE
por: Ageno, Walter, et al.
Publicado: (2017)

Thrombotic complication during intracoronary imaging
por: Wiyono, S. A., et al.
Publicado: (2012)

Intracoronary Imaging in the Detection of Vulnerable Plaques
por: Batty, Jonathan A., et al.
Publicado: (2016)

Cerebral blood flow is reduced in ME/CFS during head-up tilt testing even in the absence of hypotension or tachycardia: A quantitative, controlled study using Doppler echography
por: van Campen, C. (Linda) M.C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kp0lebf93692kfksd46676ge7s